Blood coagulation derives from a series of specific proteolytic activation reactions that are catalyzed with narrow and defined specificity by trypsin-like serine proteinases. Many of these proteinases function in membrane assembled enzyme complexes. There are major gaps in the current understanding of the molecular bases for the distinctive protein substrate specificities and the modulation of enzymic function by interactions with membranes and cofactors that are hallmarks of the proteolytic reactions of blood coagulation. This program proposes an integrated approach to focus on the contributions of macromolecular interactions to specificity and the modulation of enzymic function to explain the action of the coagulation enzymes in vivo. Project 1 (Krishnaswamy) uses the prothrombinase complex as a paradigm to investigate the role of extended macromolecular interactions between the protein substrate and the enzyme complex in explaining protein substrate specificity and cofactor function. Project 2 (Camire) will investigate the relationship between procofactor and zymogen proteolysis and the development of discrete macromolecular binding interactions that lead to the assembly of the prothrombinase complex and the expression of enzymic function. Using the x-ray structure of the catalytic domain of XIa, Project 3 (Walsh) proposes structure function studies to examine the contributions of liganding interactions at extended macromolecular recognition surfaces to XIa function. These approaches in basic biochemistry and enzymology are complemented by Project 4 (High) that proposes to use genetic mouse models to investigate the roles of factors X and Xa in vivo and explore the relative contributions of Xa formation via the extrinsic and intrinsic pathways to hemostasis and thrombosis. The objectives of the four projects will be supported by an administrative core and a core that provides support for molecular biology and protein expression. Overall, this program applies the expertise of the individual investigators towards addressing major unanswered questions in the coagulation field. The proposed approaches will provide new insights into the chemistry and biology of the blood coagulation reactions with implications for an understanding of normal hemostasis and will suggest novel therapeutic strategies for targeting thrombosis and vascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL074124-05
Application #
7266335
Study Section
Special Emphasis Panel (ZHL1-PPG-D (M1))
Program Officer
Link, Rebecca P
Project Start
2003-08-15
Project End
2009-03-31
Budget Start
2007-08-01
Budget End
2009-03-31
Support Year
5
Fiscal Year
2007
Total Cost
$1,926,136
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
Vadivel, Kanagasabai; Kumar, Yogesh; Bunce, Matthew W et al. (2017) Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: Structural insights from molecular modeling studies. Int Biol Rev 1:
Ostertag, Eric M; Bdeir, Khalil; Kacir, Stephen et al. (2016) ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. Transfusion 56:1775-85
Thalji, Nabil K; Ivanciu, Lacramioara; Davidson, Robert et al. (2016) A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22:924-32
Bradford, Harlan N; Krishnaswamy, Sriram (2016) The Fragment 1 Region of Prothrombin Facilitates the Favored Binding of Fragment 12 to Zymogen and Enforces Zymogen-like Character in the Proteinase. J Biol Chem 291:11114-23
Liang, Hai Po H; Kerschen, Edward J; Basu, Sreemanti et al. (2015) Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 126:2415-23
Pickens, Brandy; Mao, Yingying; Li, Dengju et al. (2015) Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 125:3326-34
Zheng, X Long (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211-25
Baroni, M; Pavani, G; Pinotti, M et al. (2015) Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation. Biochim Biophys Acta 1854:1351-6
George, L A; Thalji, N K; Raffini, L J et al. (2015) Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost 13:1694-8

Showing the most recent 10 out of 101 publications